Patent · IT 102022000009722
Secoiridoid polyphenols from Olea europaea stabilized
in a NaDES matrix. Intact dialdehyde form preserved.
Analytical titration per batch.
Shelf life 36 months, climatic zones IVa/IVb.
Zero organic solvents.
MDR P. aeruginosa biofilm inhibition −89.7%. Anti-virulence activity documented at sub-MIC concentrations on real clinical isolates.
The inhibitory activity of oleocanthal and oleacein on COX-1 and COX-2 has been documented in Nature since 2005. Over one hundred peer-reviewed publications describe their anti-inflammatory, antimicrobial, antiproliferative and neuroprotective properties. A systematic review in Pharmacology & Therapeutics (2024), co-authored by Active Italia, consolidates the available body of evidence.
The transition to industrial applications has been blocked by four concurrent structural problems: rapid degradation in aqueous solution at room temperature, inability to achieve standardized analytical titration per batch, incompatibility with hydroalcoholic systems, and production costs incompatible with pharmaceutical and cosmetic scale.
The CMP-NaDES process stabilizes the compounds in their intact dialdehyde form — the pharmacologically active species — within a hydrogen-bond matrix formed by food-grade/GRAS/EU-approved components (betaine, propylene glycol). 50× concentration relative to the source. 36-month shelf life in climatic zones IVa/IVb. Analytically verifiable titration per batch. Zero organic solvents. The reactivity with endogenous primary amines responsible for instability in biological matrices is intrinsic to the mechanism of action: the NaDES matrix preserves molecular integrity up to the site of application, where the compounds form biologically active adducts.
The first studies conducted with these compounds in pharmaceutically defined form on real clinical isolates were carried out by Active Italia in collaboration with Sapienza University of Rome and ISS Rome, within a structured, ongoing research programme.
Food Chemistry · Elsevier
Green synthesis of thiocanthal and thiocanthol: stable sulfonated derivatives of oleocanthal and oleacein with COX inhibitory activity superior to ibuprofen and preferential COX-2 selectivity
Aqueous-phase process, zero organic solvents. Biological activity maintained post-sulfonation. COX-2 selectivity predicted by computational docking. Sapienza University + CNR + University of Teramo.
Di Risola, Mattioli, Federico R. (Active Italia S.r.l.), Mosca et al. · DOI 10.1016/j.foodchem.2024.141296
Dermatology Reports
Palmoplantar psoriasis: lesion reduction −46%, inflammation −50%, keratinization −56% (p<0.01). Response maintained in 85% of patients at 60 days
Observational study. n=20. T0/T5/T8/T60. Zero adverse events. Active Italia CMP formulation. Sapienza Dermatology + Magna Graecia University.
Amato, Dattola, Bennardo, Tolone, Nisticò et al. · PMID 40631809
Medicina · MDPI · Randomized Clinical Trial
Wrinkle reduction −46.56% at 30 days (men 45–79y, p<0.001). PureXerum® (Active Italia S.r.l.) cited in the conclusions
Single-blind RCT. n=70. VISIA® Skin Analysis System. Men 20–44y: −51.93% (p<0.001). Women 45–79y: −33.91% (p<0.001). Zero adverse events. Sapienza University + Magna Graecia University.
Nisticò, Greco, Amato, Bennardo, Pellacani et al. · PMID 38929564
International Journal of Molecular Sciences
Biofilm inhibition of MDR P. aeruginosa −89.7%. Anti-virulence activity documented at sub-MIC concentrations on clinical isolates
Alginate −77%, pyocyanin −57%, motility −80% (p=0.000005). Clinical isolates from surgical wounds and VAP. Sapienza University + ISS Rome (Italian National Institute of Health).
Di Pietro, Filardo, Mattioli, Mosca, Sessa et al. · PMID 38732269
Frontiers in Pharmacology
S. aureus MIC 900 µg/mL · Candida MIC 202 µg/mL — best reported value in the literature. Zero cytotoxicity on human keratinocytes (HEKa)
In vitro antimicrobial activity. MTT cytotoxicity assay. NaDES matrix confirmed as pharmacologically inert. Compounds supplied by Active Italia S.r.l. Sapienza University + ISS Rome.
Di Pietro, Filardo, Mattioli, Francioso, Raponi, Mosca, Sessa et al. · DOI 10.3389/fphar.2022.885735
Pharmacology & Therapeutics · Elsevier
Olea europaea L-derived secoiridoids: beneficial health effects and potential therapeutic approaches
Neurology, oncology, metabolism, infectious diseases, IBD, dermatology. Systematic review of the international body of evidence.
Filardo, Mattioli, Di Risola, Federico R. (Active Italia S.r.l.), Mosca et al. · Pharmacol Ther 254 (2024) 108595
Dermatology
Peer-reviewed clinical studies completed. Registered products. Active development programme.
Women's intimate health
Two operative formulations. Dedicated IP under examination.
Gastroenterology
Preclinical data completed. Clinical trial initiating.
Wound Healing
Registered products. Regulatory pathway under definition.
Antimicrobial Resistance
Four PMID publications. Preclinical programme active. Regulatory pathway under definition.
Active Italia was founded by scientists with decades of published research on the biochemistry of secoiridoids — before an industrial market for these compounds existed. Clinical and preclinical studies are conducted in collaboration with Sapienza University of Rome, ISS Rome and other independent academic centres.
The CMP-NaDES platform is the result of that journey: a patented process that translates decades of molecular knowledge into an industrially defined, titrated, reproducible active ingredient. Not an extract. A compound.
Publications in Nature, Food Chemistry, Pharmacology & Therapeutics, Frontiers in Pharmacology and International Journal of Molecular Sciences document a coherent scientific trajectory — not a retrospective validation campaign.
